Angiogenesis inhibitors: Nursing pharmacology
Video summary
Angiogenesis inhibitors are a class of drug that inhibits the formation of new blood vessels. They treat cancer as tumors require a blood supply to grow.
Angiogenesis inhibitors work by blocking the receptors on endothelial cells that signal for new blood vessel formation, which prevents the tumor from getting the nutrients it needs to grow. Common examples of angiogenesis inhibitors include Axitinib, Bevacizumab, and Cabozantinib.
Angiogenesis inhibitors are medications mainly used to treat cancers like non-small cell lung cancer, cervical cancer, metastatic colorectal cancer, metastatic renal cell carcinoma, and recurrent glioblastoma. In addition, these medications can be used to treat macular degeneration.
The most commonly used angiogenesis inhibitor is bevacizumab, which is a monoclonal antibody that’s administered intravenously for cancer treatment, and intravitreal for macular degeneration. Once administered, bevacizumab acts by binding to the protein human vascular endothelial growth factor, or VEGF for short, which helps promote angiogenesis, meaning the formation of new blood vessels throughout the body. So, bevacizumab inhibits the activity of VEGF, ultimately reducing the progression of cancer or macular degeneration.
Now, bevacizumab may often lead to side effects, such as headaches, dizziness, or syncope. In addition, some clients may present with injection-site infusion reactions or exfoliative dermatitis. Other common side effects include abdominal pain, anorexia, nausea, vomiting, or diarrhea.
Clients on bevacizumab may also develop heart failure, hypertension, and venous thromboembolism; as well as thrombocytopenia, leukopenia, and increased risk of infections. Additional side effects include dyspnea, epistaxis, hemoptysis, and vaginal bleeding. Finally, bevacizumab can potentially cause gastrointestinal perforation and bleeding, as well as wound dehiscence.
Regarding contraindications, bevacizumab should be used with caution in clients with serious bleeding or hypertensive crisis, and it should not be used 28 days before and after surgery, since it can interfere with wound healing. In addition, bevacizumab should be used cautiously during pregnancy and breastfeeding, as well as in children and elderly clients. Other precautions include clients with cardiovascular or thromboembolic disease.
| ANGIOGENESIS INHIBITORS | ||
| DRUG NAME | bevacizumab (Avastin, Mvasi, Zirabev) *High Alert Medication* | |
| CLASS | Angiogenesis inhibitor | |
| MECHANISM of ACTION | Binding to VEGF → inhibit angiogenesis, ultimately reducing cancer progression | |
| INDICATIONS |
| |
| ROUTE(S) of ADMINISTRATION |
| |
| SIDE EFFECTS |
| |
| CONTRAINDICATIONS & CAUTIONS |
| |
| NURSING CONSIDERATIONS for ANGIOGENESIS INHIBITORS | ||
| ASSESSMENT & MONITORING | Assessment & monitoring: Bevacizumab for recurrent glioblastoma Assessment
Administration
Monitoring
| |
| CLIENT EDUCATION |
| |
- "Karch’s Focus on Nursing Pharmacology, 9th edition" LWW (2023)
- "Pharmacology: A Patient-Centered Nursing Process Approach, 9th edition" Elsevier Canada (2020)
- "Mosby’s 2023 Nursing Drug Reference, 36th edition" Mosby (2022)
- "Tumor angiogenesis: causes, consequences, challenges and opportunities" Cell Mol Life Sci (2020)
- "Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers" International Journal of Molecular Sciences (2020)
- "Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions" J Immunother Cancer (2019)
Aún no hay notas para este video
Intenta agregar una nota a continuación